Last reviewed · How we verify
NCT05534958
UK Validation of the Automated "AcceXible" Speech Analysis Software
trial testing Accexible in Mild Cognitive Impairment and Dementia in 221 participants. Completed in 31 December 2024.
12 November 2024
Quick facts
| Lead sponsor | Accexible |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 221 |
| Start date | 18 November 2022 |
| Primary completion | 12 November 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Accexible
Conditions studied
- Mild Cognitive Impairment and Dementia — all drugs for Mild Cognitive Impairment and Dementia →
Sponsor
Accexible — full company profile →
Who can join
Adults 55 to 90, any sex, with Mild Cognitive Impairment and Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear. The sooner the patient is diagnosed, the sooner the patient will be in a position to prevent further deterioration. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. The present study has the objective of validating a digital method for detection and follow-up of patients with mild cognitive impairment (MCI) or dementia in a memory clinic setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05534958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Accexible
Trials testing the same drug.
- NCT06044818 — Validation of Accexible as a Tool for Screening and Monitoring Depression. · completed
Other Accexible trials
Trials by the same sponsor.
- NCT06044818 — Validation of Accexible as a Tool for Screening and Monitoring Depression. · completed
- NCT05380297 — Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild · NA · completed
- NCT05340218 — Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05534958 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Accexible
- Last refreshed: 27 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05534958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing